EL
ELOX.US Eloxx Pharmaceuticals, Inc.
- Market cap
- USD 53.1M
- P/E
- 3.7x
- P/B
- 1.13x
- ROE
- -35.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ELOX.US undervalued?
Graham numberELOX.US trades 56.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eloxx Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for Eloxx Pharmaceuticals, Inc. yet.
Eloxx Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with n…
Full company profileEloxx Pharmaceuticals, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eloxx Pharmaceuticals, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 75.0K | - | - | - | - | - | 0.00 | 0.00 | 6.36M | 0.00 | 0.00 |
| Gross Profit | -18.4K | -39.0K | -216K | -559K | -571K | -960K | -695K | - | 6.36M | - | - |
| Operating Income | -3.71M | -20.4M | -47.0M | -50.6M | -29.4M | -42.3M | -34.4M | -17.3M | -2.47M | -6.44M | -16.5M |
| EBITDA | -3.62M | -20.4M | -46.8M | -50.0M | -28.9M | -64.5M | -33.5M | -15.1M | -1.84M | -4.95M | -16.4M |
| Net Income | -8.27M | -21.2M | -47.2M | -50.9M | -34.6M | -66.7M | -36.1M | -17.1M | -3.14M | -6.00M | -16.5M |
| EPS | -3,581 | -1,876 | -640 | -588 | -379 | -420 | -183 | -73 | -9.20 | -5.34 | -2.43 |
| Balance Sheet | |||||||||||
| Total Assets | 9.23M | 24.8M | 50.7M | 58.9M | 26.5M | 45.1M | 21.1M | 1.71M | 2.98M | 5.27M | 63.4M |
| Total Liabilities | 4.67M | 3.42M | 7.81M | 22.7M | 16.2M | 22.8M | 31.8M | 24.3M | 27.3M | 17.2M | 17.0M |
| Shareholders' Equity | 4.56M | 21.4M | 42.9M | 36.2M | 10.2M | 22.4M | -10.7M | -22.6M | -24.3M | -11.9M | 46.4M |
| Cash & Short-term Investments | 811K | 24.2M | 48.7M | 56.3M | 24.7M | 42.6M | 19.5M | 1.13M | 111K | 4.79M | 62.0M |
| Total Debt | - | - | - | 15.8M | 12.0M | 13.5M | 13.4M | 3.97M | 6.52M | 1.00M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.68M | -15.9M | -31.4M | -39.4M | -28.2M | -35.0M | -31.8M | -14.3M | -4.72M | -6.33M | -20.5M |
| Capital Expenditure | 5.00 | 237K | 235K | 40.0K | 0.00 | 89.0K | 66.0K | 0.00 | 0.00 | 6.33M | 0.00 |
| Free Cash Flow | -3.68M | -16.2M | -31.6M | -39.4M | -28.2M | -35.1M | -31.9M | -14.3M | -4.72M | -6.33M | -20.5M |
| Ratios | |||||||||||
| ROE | -181.3% | -99.3% | -110.0% | -140.5% | -338.0% | -298.1% | - | - | - | - | -35.6% |
| ROA | -89.6% | -85.6% | -93.0% | -86.3% | -130.6% | -147.8% | -170.7% | -996.1% | -105.6% | -113.8% | -26.0% |
| Net Profit Margin | -11,023.9% | - | - | - | - | - | - | - | -49.4% | - | - |
| Debt to Equity | - | - | - | 0.44x | 1.18x | 0.60x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eloxx Pharmaceuticals, Inc. dividends
Eloxx Pharmaceuticals, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:11 on Jun 1, 2026.
Who owns Eloxx Pharmaceuticals, Inc.
- Insiders 19.10%
- Institutions 78.88%
- Public & others 2.02%
- Shares outstanding 4.04M
- Free float 933K
Top funds holding ELOX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn Healthcare Investors | 269K | 6.67% | 0.00% | Sep 2026 |
| abrdn Life Sciences Investors | 131K | 3.24% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 57.5K | 1.42% | 0.00% | Sep 2026 |
| EQ/Morgan Stanley Small Cap Growth K | 40.0K | 0.99% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 10.9K | 0.27% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.29K | 0.06% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 1.69K | 0.04% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 1.04K | 0.03% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 877.00 | 0.02% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 718.00 | 0.02% | 0.00% | Sep 2026 |
| Counterpoint Global CIBC U.S. Sm CpGrETF | 155.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding ELOX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 800K | 19.82% | 0.00% | Jun 2026 |
| EcoR1 Capital, LLC | 400K | 9.91% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 400K | 9.91% | 0.00% | Jun 2026 |
| Samsara BioCapital, LLC | 400K | 9.91% | 0.00% | Jun 2026 |
| Aberdeen Group PLC | 400K | 9.91% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 397K | 9.84% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 78.7K | 1.95% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 10.6K | 0.26% | 0.00% | Jun 2026 |
| SEVEN GRAND MANAGERS, LLC | 10.0K | 0.25% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.54K | 0.04% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 718.00 | 0.02% | 0.00% | Jun 2026 |
| UBS Group AG | 637.00 | 0.02% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 126.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 98.00 | 0.00% | 0.00% | Jun 2026 |
| Pioneer Family Office, LLC | 96.00 | 0.00% | 0.00% | Sep 2026 |
| Altshuler Shaham Ltd | 25.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 12.00 | 0.00% | 0.00% | Jun 2026 |
| OLD POINT TRUST & FINANCIAL SERVICES N A | 5.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Activest Wealth Management | 4.00 | 0.00% | 0.00% | Jun 2026 |
Eloxx Pharmaceuticals, Inc. company profile
- Company name
- Eloxx Pharmaceuticals, Inc.
- Ticker
- ELOX.US
- Exchange
- USA Stocks
- Listed since
- Jun 9, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- P.O. Box 274, Arlington, MA, United States, 02476
- Phone
- 781 577 5300
- Website
- eloxxpharma.com
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Eloxx Pharmaceuticals, Inc. management
6- Mr. Sumit Aggarwal M.B.A.President, CEO & Director · born 1973
- Mr. Daniel E. Geffken M.B.A.Interim Chief Financial Officer · born 1957
- Mr. John WoolfordVP & Head of Corporate Development
- Dr. Roger ClarkVP & Head of Discovery Sciences
- Dr. Teji SinghVP & Head of Clinical Development
- Dr. Titte R. Srinivas M.D.Senior VP & Chief Medical Officer